Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says

November 5, 2021 By Sean Whooley

Edwards-Commander — Edwards Lifesciences created its Commander delivery system for its Sapien 3 TAVR. [Image courtesy of Edwards]

Edwards Lifesciences (NYSE:EW) today touted a cost-effectiveness analysis that supports transcatheter aortic valve replacement (TAVR) with the Sapien 3.

Irvine, California-based Edwards presented data from the Partner 3 trial during the late-breaking clinical trials at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

Get the full story on our sister site MassDevice.

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.